Wells Fargo lowered the firm’s price target on Affimed to $25 from $30 and keeps an Overweight rating on the shares. Following review of company Q4 2023 update, the firm remains optimistic that the Phase 2 LuminICE-203 study of AFM13 + AB-101 can meet the bar set by KOLs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFMD: